SCHEMBL23613612

SCHEMBL23613612

CC(C)C(N)C(=O)Nc1ccc2[nH]c(Cc3c[nH]c4ccccc34)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSC P53634 1/20 0.49
KRAS P01116 1/20 0.47
MAPK1 P28482 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 1/20 0.43
STAT3 P40763 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RUVBL1 Q9Y265 2/20 0.42
GPR84 Q9NQS5 1/20 0.42
PKM P14618 1/20 0.42
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
GHSR Q92847 1/20 0.41
AKT1 P31749 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23613610 1.00 CTSC (0.49) CTSCKRASMAPK1SMN1; SMN2MAPT
SCHEMBL23613495 0.92 KRAS (0.48) CTSCKRASMAPK1SMN1; SMN2MAPT
SCHEMBL23612886 0.92 KRAS (0.45) CTSCKRASMAPK1SMN1; SMN2MAPT
SCHEMBL23612884 0.92 KRAS (0.45) CTSCKRASMAPK1SMN1; SMN2MAPT
SCHEMBL23613607 0.92 KRAS (0.45) CTSCKRASMAPK1SMN1; SMN2MAPT
SCHEMBL19626542 0.85 KRAS (0.46) CTSCKRASMAPK1SMN1; SMN2MAPT
SCHEMBL23613591 0.83 MAPT (0.52) KRASMAPK1SMN1; SMN2MAPTMEN1
SCHEMBL23613613 0.82 MAPT (0.56) KRASMAPK1MAPTMEN1KMT2A
SCHEMBL19630743 0.81 KRAS (0.47) CTSCKRASMAPK1SMN1; SMN2MAPT
SCHEMBL23613603 0.80 HDAC1 (0.45) KRASMAPK1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11052154-B2 Ras protein degradation inducing molecule and pharmaceutical composition TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2021-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052154-B2 Ras protein degradation inducing molecule and pharmaceutical composition KRAS, G3BP1, NRAS CTSC 773/4885KRAS 1/4885MAPK1 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.